Two-Year Therapeutic Efficacy and Safety of Initial Triple Combination of Metformin, Sitagliptin, and Empagliflozin in Drug-Naïve Type 2 Diabetes Mellitus Patients (Diabetes Metab J 2024;48:253-64)

MeSH terms

• Aged
• Benzhydryl Compounds* / administration & dosage
• Benzhydryl Compounds* / therapeutic use
• Blood Glucose / analysis
• Diabetes Mellitus, Type 2* / complications
• Diabetes Mellitus, Type 2* / drug therapy
• Drug Therapy, Combination*
• Female
• Glucosides* / administration & dosage
• Glucosides* / therapeutic use
• Glycated Hemoglobin / analysis
• Humans
• Hypoglycemic Agents* / administration & dosage
• Hypoglycemic Agents* / therapeutic use
• Male
• Metformin* / administration & dosage
• Metformin* / therapeutic use
• Middle Aged
• Sitagliptin Phosphate* / administration & dosage
• Sitagliptin Phosphate* / therapeutic use
• Sodium-Glucose Transporter 2 Inhibitors / administration & dosage
• Sodium-Glucose Transporter 2 Inhibitors / therapeutic use
• Treatment Outcome